CJC1295 (No DAC) + Ipamorelin 10mg

COMING SOON

$45.00

Out of stock

RE-STOCK PENDING - EXPECTED EARLY JULY

CJC-1295 (No DAC) + Ipamorelin 10mg

CJC-1295 (no DAC) + Ipamorelin is the gold standard GH-stimulating stack. CJC-1295 is a short-acting GHRH analog with a 30-minute half-life that triggers pulsatile GH release, while Ipamorelin is a selective GHRP that amplifies those pulses through a different receptor pathway. Together they produce synergistic GH elevation without the side effects (cortisol, prolactin elevation, hunger) seen with other GHRPs.

Intended Use and Disclaimer:

For laboratory and research use only. Not for human or veterinary use. This product is not intended for injection, ingestion, or clinical applications.

This product has not been evaluated by the FDA and is not intended to prevent, diagnose, treat, or cure any disease. Must be used by qualified professionals in a sterile laboratory setting.

By purchasing from Optitide Research, the buyer agrees and affirms they are a qualified researcher or institution. All sales are final. Proper handling, use, and disposal are the sole responsibility of the purchaser.

Optitide Research supplies research-grade peptides exclusively to qualified research professionals and institutions in the USA.

Contact

Newsletter

info@optitideresearch.com

209-624-0715

Terms & Conditions

All materials offered by Optitide Research are supplied strictly for laboratory research and development use. These products are not intended for human ingestion or clinical application. The content and claims presented on this website have not been reviewed or approved by the U.S. Food and Drug Administration (FDA). None of the statements or products provided by Optitide Research are designed to diagnose, mitigate, treat, cure, or prevent any disease.

Optitide Research operates solely as a product supplier. The company is not a compounding pharmacy or chemical compounding facility under Section 503A of the Federal Food, Drug, and Cosmetic Act, nor is it an outsourcing facility as defined under Section 503B of the same Act.